Sign in

    Ken Mestemacher

    Research Analyst at Edison Group

    Ken Mestemacher is a Director of TMT (Technology, Media, and Telecommunications) Research at Edison Group, specializing in software, smart city, gaming, and surveillance sectors. He has covered companies including SenSen Networks and InMed Pharmaceuticals, providing fundamental equity analysis and research insights to global investors, though public quantitative success metrics and rankings are not currently disclosed. Mestemacher holds the Chartered Financial Analyst (CFA) designation and has an MBA with a finance concentration, reflecting a strong foundation in both technical and financial disciplines. He has established his career primarily at Edison Group, where he leads technology sector coverage and regularly contributes to the firm's published research reports.

    Ken Mestemacher's questions to InMed Pharmaceuticals (INM) leadership

    Ken Mestemacher's questions to InMed Pharmaceuticals (INM) leadership • Q2 2022

    Question

    Ken Mestemacher of Edison Group questioned the rationale for selecting CBDV and THCV as the next product launches and their pricing dynamics. He also asked about the ideal timing for partnering the INM-088 glaucoma program and sought details on the role of the newly hired VP of Sales and Marketing.

    Answer

    CEO Eric Adams and Shane Johnson, SVP and GM of BayMedica, explained that CBDV and THCV were chosen due to strong customer demand and existing scientific data supporting their use cases, with current market prices around $25,000 per kilogram. Regarding the glaucoma program, Eric Adams and Eric Hsu, SVP of Preclinical R&D, noted that partnerships in the ocular space can occur early, even preclinically. Shane Johnson detailed that the new VP of Sales, Jerry Griffin, will spearhead all sales and marketing efforts, focusing on expanding within the wellness channel and opening new markets like personal care and food & beverage.

    Ask Fintool Equity Research AI